Drug
Emd525797
Emd525797: highest development phase Phase 1, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| EMD525797 NCT01327313 | Phase 1 | Solid Tumor |
Latest
No recent events.
Follow Emd525797 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.